PACE-LUNG
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment
II
interventionell
National
Osimertinib is the investigational medical product when administered concomitantly with platinum-based chemotherapy
Status: In Rekrutierung
Zeitraum
2021
2024
Patienten
50
3
07.11.2022
Klinische Settings
IV, IVA, IVB, IVC
1st line
palliativ
Beteiligte
AIO-Arbeitsgruppen
Sponsor
Goethe University Hospital Frankfurt
Kooperierende Fachgesellschaft(en)
nNGM
Förderer
Astra Zeneca
Identifier
AIO-TRK-0422/ass
2019-004757-88
Kontakt
Leitung
Dr. med. Martin Sebastian
Ansprechpartner*in
Dr. med. Martin Sebastian
Telefon +49 69 63015677
E-Mail Martin.Sebastian@kgu.de